Probiotic Ameliorates Adult Allergic Rhinitis and Modulates Gut Microbiota

Inclusion Criteria:

1. Voluntarily and in writing, sign an informed consent form agreeing to participate inthis study;

2. Able to complete the study as required by the trial protocol;

3. Age between 18 and 65 years old;

4. Meet the diagnostic criteria for allergic rhinitis established in the "ChineseGuidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022 RevisedEdition)";

5. Symptoms: Presence of two or more symptoms such as sneezing, watery rhinorrhea,nasal itching, and nasal congestion, with daily symptoms lasting or accumulating formore than 1 hour, which may be accompanied by eye itching, tearing, and redness ofthe eyes and other ocular symptoms;

6. Signs: Pale and edematous nasal mucosa, which may be accompanied by waterysecretions.

Exclusion Criteria:

1. Use of drugs affecting the gut microbiota (including antimicrobial agents,probiotics, intestinal mucosal protective agents, traditional Chinese patentmedicines, etc.) for more than 1 week within 1 month prior to screening;

2. Patients with coexisting pulmonary tuberculosis;

3. Patients with coexisting allergic asthma;

4. Patients with nasal polyps or severe nasal septum deviation;

5. Patients with severe systemic diseases or malignant tumors;

6. Individuals with congenital genetic diseases or congenital immunodeficiencydiseases;

7. Regular use of probiotics or prebiotics within 6 months prior to the screeningperiod;

8. Patients with severe gastrointestinal diseases (including severe diarrhea,inflammatory bowel diseases, etc.);

9. Individuals with metabolic syndrome (including obesity, dyslipidemia, hypertension,diabetes, etc.);

10. Patients with sinusitis, otitis media, or respiratory tract infections;

11. Individuals allergic to any components of the probiotics used in this trial;

12. Pregnant or lactating women or those planning to conceive in the near future;

13. Those who discontinue the test sample or take other medications midway, making itimpossible to determine efficacy or with incomplete data;

14. Recent use of products similar to the test function, affecting the judgment of theresults;

15. Participants who cannot participate in the trial due to their own reasons;

16. Other participants deemed ineligible by the researcher.